Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections

International Journal of Antimicrobial Agents

Volumn 39, Issue 5, 2012, Pages 376-380

  Amaral, Leonard ^a   Viveiros, Miguel ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Cure; Enhanced intracellular killing; Inhibition of efflux pumps; MDR TB; TDR TB; Thioridazine; XDR TB

Indexed keywords

ANTIBIOTIC AGENT; CHLORPROMAZINE; ISONIAZID; RIFAMPICIN; THIORIDAZINE;

AKATHISIA; AMENORRHEA; AMNESIA; ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; CARDIOTOXICITY; CELL MEMBRANE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; EFFLUX PUMP; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GROWTH INHIBITION; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMPOTENCE; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TOTALLY DRUG RESISTANT TUBERCULOSIS;

EID: 84859428822     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.01.012     Document Type: Short Survey

References (81)

1. Dreaper J. TB: plan to tackle rise in drug-resistant cases. BBC Mobile News Health 13 September 2011.
2. Z.F. Udwadia, R.A. Amale, K.K. Ajbani, and C. Rodrigues Totally drug-resistant tuberculosis in India Clin Infect Dis 54 2012 579 581
3. B. Mercurio Resolving the public health crisis in the developing world: problems and barriers of access to essential medicines Northwestern Univ J Int Hum Rights 5 2007 http://www.law.northwestern.edu/journals/jihr/v5/n1/1 [accessed 15 February 2012]
4. S.S. Rajbhandary, S.M. Marks, and N.N. Bock Costs of patients hospitalized for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 8 2004 1012 1016 (Pubitemid 39024906)
5. British Medical Association and the Royal Pharmaceutical Society of Great Britain British National Formulary, No. 60 2010 BMJ & Pharmaceutical Press London, UK 214
6. L. Amaral, and J.E. Kristiansen Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies Int J Antimicrob Agents 14 2000 173 176 (Pubitemid 30201540)
7. L. Amaral, J.E. Kristiansen, M. Viveiros, and J. Atouguia Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy J Antimicrob Chemother 47 2001 505 511 (Pubitemid 32447635)
8. J.E. Kristiansen, and L. Amaral The potential management of resistant infections with non-antibiotics J Antimicrob Chemother 40 1997 319 327 (Pubitemid 27437949)
9. J. Molnár, I. Béládi, and I. Földes Studies on antituberculotic action of some phenothiazine derivatives in vitro Zentralbl Bakteriol Orig A 239 1977 521 526 (Pubitemid 8293540)
10. J.E. Kristiansen, and B. Vergmann The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria Acta Pathol Microbiol Immunol Scand B 94 1986 393 398 (Pubitemid 17008869)
11. S.J. Klein, and B.E. Naizby Creation of a tuberculosis directly observed therapy provider network in New York City: a new model of public health J Public Health Manag Pract 1 1995 1 6
12. L. Amaral, M. Viveiros, and J. Molnar Antimicrobial activity of phenothiazines In Vivo 18 2004 725 731
13. M. Viveiros, M. Martins, I. Couto, J.E. Kristiansen, J. Molnar, and L. Amaral The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient In Vivo 19 2005 733 736 (Pubitemid 40903270)
14. L. Amaral, M. Martins, and M. Viveiros Phenothiazines as anti-multi-drug resistant tubercular agents Infect Disord Drug Targets 7 2007 257 265 (Pubitemid 350028059)
15. A.J. Crowle, G.S. Douvas, M.H. May, and Chlorpromazine: a drug potentially useful for treating mycobacterial infections Chemotherapy 38 1992 410 419 (Pubitemid 23054943)
16. W.A. Daniel, and J. Wójcikowski Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants Eur Neuropsychopharmacol 9 1999 483 491 (Pubitemid 30089061)
17. L. Amaral, J.E. Kristiansen, L.S. Abebe, and W. Millett Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis J Antimicrob Chemother 38 1996 1049 1053 (Pubitemid 27073284)
18. M.V. Bettencourt, S. Bosne-David, and L. Amaral Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis Int J Antimicrob Agents 16 2000 69 71 (Pubitemid 30665428)
19. D. Ordway, M. Viveiros, C. Leandro, R. Bettencourt, J. Almeida, and M. Martins Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 917 922 (Pubitemid 36254216)
20. M. Martins, M. Viveiros, and L. Amaral The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics Future Microbiol 3 2008 135 144 (Pubitemid 351984062)
21. L. Amaral, M. Martins, M. Viveiros, J. Molnar, and J.E. Kristiansen Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps Curr Drug Targets 9 2008 816 819
22. M. Martins, M. Viveiros, J. Ramos, I. Couto, J. Molnar, and M. Boeree SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB) Int J Antimicrob Agents 33 2009 479 482
23. M. Martins, Z. Schelz, A. Martins, J. Molnar, G. Hajös, and Z. Riedl In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis Int J Antimicrob Agents 29 2007 338 340
24. M. Martins, M. Viveiros, J.E. Kristiansen, J. Molnar, and L. Amaral The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis In Vivo 21 2007 771 775
25. D. van Soolingen, R. Hernandez-Pando, H. Orozco, D. Aguilar, C. Magis-Escurra, and L. Amaral The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis PLoS One 5 2010 pii:e12640
26. L. Amaral, M. Viveiros, J. Molnar, and J.E. Kristiansen Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses" Recent Pat Antiinfect Drug Discov 6 2011 84 87
27. E. Abbate, M. Vescovo, M. Natiello, M. Cufré, A. Garcia, and M. Ambroggi Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos Revista Argentina de Medicina Respiratoria 1 2007 19 25
28. E. Abbate, M. Vescovo, M. Natiello, M. Cufré, A. García, and P. Gonzalez Montaner Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine J Antimicrob Chemother 67 2012 473 477
29. Z.F. Udwadia, T. Sen, and L.M. Pinto Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB Recent Pat Antiinfect Drug Discov 6 2011 88 91
30. L. Amaral, M.J. Boeree, S.H. Gillespie, Z.F. Udwadia, and D. van Soolingen Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now Int J Antimicrob Agents 35 2010 524 526
31. A. Martins, L. Machado, S. Costa, P. Cerca, G. Spengler, and M. Viveiros Role of calcium in the efflux system of Escherichia coli Int J Antimicrob Agents 37 2011 410 414
32. W.N. Hait, and J.S. Lazo Calmodulin: a potential target for cancer chemotherapeutic agents J Clin Oncol 4 1986 994 1012 (Pubitemid 16080956)
33. C.B. Klee, W.C. Ni, G.F. Draetta, and D.L. Newton Different modes of interaction of calmodulin with its target enzymes J Cardiovasc Pharmacol 8 Suppl. 8 1986 S52 S56
34. B.L. Brown, S.W. Walker, and S. Tomlinson Calcium calmodulin and hormone secretion Clin Endocrinol (Oxf) 23 1985 201 218 (Pubitemid 15015343)
35. H. Hidaka, and K. Shikano Overview on the research on calmodulin and its inhibitors Nihon Rinsho 41 1983 2138 2150 [in Japanese]
36. S.B. Oldham Calmodulin: its role in calcium-mediated cellular regulation Miner Electrolyte Metab 8 1982 1 12 (Pubitemid 12063215)
37. D.J. Kusner Mechanisms of mycobacterial persistence in tuberculosis Clin Immunol 114 2005 239 247 (Pubitemid 40255129)
38. K. Ayub, and M.B. Hallett Signalling shutdown strategies in aging immune cells Aging Cell 3 2004 145 149 (Pubitemid 40246679)
39. B.A. Burleigh, and N.W. Andrews Signaling and host cell invasion by Trypanosoma cruzi Curr Opin Microbiol 1 1998 461 465 (Pubitemid 128423263)
40. C.R. Hoyal, J. Girón-Calle, and H.J. Forman The alveolar macrophage as a model of calcium signaling in oxidative stress J Toxicol Environ Health B Crit Rev 1 1998 117 134 (Pubitemid 128692522)
41. 2+ influx mechanisms Sci China Life Sci 54 2011 763 769
42. 2+ signaling in mast cells: potential targets for treatment of mast cell-related diseases? Adv Exp Med Biol 716 2011 62 90
43. 2+ pump inhibitors Biochem Soc Trans 39 2011 789 797
44. G.R. Khodus, M. Kruusmägi, J. Li, X.L. Liu, and A. Aperia Calcium signaling triggered by ouabain protects the embryonic kidney from adverse developmental programming Pediatr Nephrol 26 2011 1479 1482
45. D.B. Tikhonov, and L.G. Magazanik The diversity of mechanisms of the ion channels blockade as a way towards designing new pharmacological agents Ross Fiziol Zh Im I M Sechenova 96 2010 726 739 [in Russian]
46. D.L. Cioffi, C. Barry, and T. Stevens Store-operated calcium entry channels in pulmonary endothelium: the emerging story of TRPCS and Orai1 Adv Exp Med Biol 661 2010 137 154
47. D. Bartosiewicz, and A. Krasowska Inhibitors of ABC transporters and biophysical methods to study their activity Z Naturforsch C 64 2009 454 458
48. Z.K. Sweeney, A. Minatti, D.C. Button, and S. Patrick Small-molecule inhibitors of store-operated calcium entry ChemMedChem 4 2009 706 718
49. G.S. Bird, W.I. DeHaven, J.T. Smyth, and J.W. Putney Jr. Methods for studying store-operated calcium entry Methods 46 2008 204 212
50. L. Schlichter, N. Sidell, and S. Hagiwara Potassium channels mediate killing by human natural killer cells Proc Natl Acad Sci USA 83 1986 451 455 (Pubitemid 16080031)
51. + channel is essential for innate immunity Nature 427 2004 853 858 (Pubitemid 38297748)
52. + flux Nature 416 2002 291 297 (Pubitemid 34260237)
53. + transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB) - a novel, patentable approach to limit the emergence of XDR-TB Recent Pat Antiinfect Drug Discov 6 2011 110 117
54. + transport enhance intracellular killing of M. tuberculosis by non-killing macrophages In Vivo 22 2008 69 75
55. L. Amaral, A. Martins, J. Molnar, J.E. Kristiansen, M. Martins, and M. Viveiros Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB In Vivo 24 2010 409 424
56. M.D. Routh, Y. Zalucki, C.C. Su, Q. Zhang, W.M. Shafer, and E.W. Yu Efflux pumps of the resistance-nodulation-division family: a perspective of their structure, function, and regulation in Gram-negative bacteria Adv Enzymol Relat Areas Mol Biol 77 2011 109 146
57. L. Amaral, S. Fanning, and J.M. Pags Efflux pumps of Gram-negative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines Adv Enzymol Relat Areas Mol Biol 77 2011 61 108
58. J.M. Pags, L. Amaral, and S. Fanning An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat Gram-negative resistant bacteria Curr Med Chem 18 2011 2969 2980
59. J.M. Blair, and L.J. Piddock Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update Curr Opin Microbiol 12 2009 512 519
60. L.J. Piddock Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria Clin Microbiol Rev 19 2006 382 402
61. K. Poole Efflux pumps as antimicrobial resistance mechanisms Ann Med 39 2007 162 176 (Pubitemid 46676478)
62. P.E. da Silva, A. Von Groll, A. Martin, and J.C. Palomino Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis FEMS Immunol Med Microbiol 63 2011 1 9
63. X.Z. Li, and H. Nikaido Efflux-mediated drug resistance in bacteria: an update Drugs 69 2009 1555 1623
64. M. Viveiros, C. Leandro, and L. Amaral Mycobacterial efflux pumps and chemotherapeutic implications Int J Antimicrob Agents 22 2003 274 278 (Pubitemid 37103213)
65. L. Rodrigues, D. Machado, I. Couto, L. Amaral, and M. Viveiros Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex Infect Genet Evol 2011 10.1016/j.meegid.2011.08.009
66. L. Rodrigues, J.A. Aínsa, L. Amaral, and M. Viveiros Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors Recent Pat Antiinfect Drug Discov 6 2011 118 127
67. L. Rodrigues, J. Ramos, I. Couto, L. Amaral, and M. Viveiros Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance BMC Microbiol 11 2011 35
68. L. Rodrigues, D. Sampaio, I. Couto, D. Machado, W.V. Kern, and L. Amaral The role of efflux pumps in macrolide resistance in Mycobacterium avium complex Int J Antimicrob Agents 34 2009 529 533
69. I.K. Neonakis, D.A. Spandidos, and E. Petinaki Confronting multidrug-resistant Acinetobacter baumannii: a review Int J Antimicrob Agents 37 2011 102 109
70. H. Giamarellou Multidrug-resistant Gram-negative bacteria: how to treat and for how long Int J Antimicrob Agents 36 Suppl. 2 2010 S50 S54
71. F. Barbier, and M. Wolff Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end? Med Sci (Paris) 26 2010 960 968 [in French]
72. V. Dartois, and C.E. Barry Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis Curr Clin Pharmacol 5 2010 96 114
73. H. Giamarellou, and G. Poulakou Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69 2009 1879 1901
74. M. Viveiros, I. Portugal, R. Bettencourt, T.C. Victor, A.M. Jordaan, and C. Leandro Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis Antimicrob Agents Chemother 46 2002 2804 2810
75. G.E. Louw, R.M. Warren, N.C. Gey van Pittius, R. Leon, A. Jimenez, and R. Hernandez-Pando Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux Am J Respir Crit Care Med 184 2011 269 276
76. N.K. Dutta, K. Mazumdar, S.G. Dastidar, P.C. Karakousis, and L. Amaral New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective Recent Pat Antiinfect Drug Discov 6 2011 128 138
77. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M., 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis, in press.
78. J.M. Pags, and L. Amaral Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria Biochim Biophys Acta 1794 2009 826 833
79. L. Amaral, and J.M. Pags Control and regulation of permeability of MDR bacterial pathogens to antibiotics presented by COST Action BM0701 Curr Drug Targets 9 2008 718
80. A. Martins, C. Iversen, L. Rodrigues, G. Spengler, J. Ramos, and W.V. Kern An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators Int J Antimicrob Agents 34 2009 602 604
81. C. Sohaskey Latent tuberculosis: is there a role for thioridazine? Recent Pat Antiinfect Drug Discov 6 2011 139 146